Pages that link to "Q26781634"

The following pages link to The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs (Q26781634):

Displaying 32 items.

• Recent advances in understanding apicomplexan parasites (Q26747055) (← links)
• Muddled mechanisms: recent progress towards antimalarial target identification (Q28066421) (← links)
• New developments in anti-malarial target candidate and product profiles (Q28468598) (← links)
• Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites (Q28551519) (← links)
• Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway (Q28821118) (← links)
• Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor (Q28830547) (← links)
• The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens (Q30042965) (← links)
• Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733. (Q36380610) (← links)
• Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways (Q37358648) (← links)
• Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes (Q37414137) (← links)
• The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy (Q37576360) (← links)
• Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria (Q37613014) (← links)
• Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. (Q38695331) (← links)
• Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4. (Q38715752) (← links)
• Phenotypic Screens in Antimalarial Drug Discovery (Q38849773) (← links)
• Antimalarial Drug Resistance: A Threat to Malaria Elimination (Q39176615) (← links)
• Functional characterization of the Ca2+-ATPase SMA1 from Schistosoma mansoni (Q47305080) (← links)
• Targeting Channels and Transporters in Protozoan Parasite Infections. (Q52594992) (← links)
• Drugs in Development for Malaria. (Q55278895) (← links)
• Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis. (Q55334152) (← links)
• Biochemical characterization and chemical inhibition of PfATP4-associated Na-ATPase activity in membranes (Q56341251) (← links)
• Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro (Q56344152) (← links)
• Malaria (Q56378965) (← links)
• Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials (Q56379943) (← links)
• Bioinformatics Analysis and Functional Prediction of Transmembrane Proteins in (Q58554728) (← links)
• Enzymatic Transition States and Drug Design (Q58594217) (← links)
• The past, present and future of anti-malarial medicines (Q62983704) (← links)
• Natural Product Inspired Novel Indole based Chiral Scaffold Kills Human Malaria Parasites via Ionic Imbalance Mediated Cell Death (Q91526716) (← links)
• Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin? (Q91807435) (← links)
• A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4 (Q91936969) (← links)
• The genomic architecture of antimalarial drug resistance (Q92231044) (← links)
• Wikidata:Database reports/Constraint violations/P275 (← links | edit)